Scientists in Japan have discovered a genetic "silencer" within the HTLV-1 virus that helps it stay hidden in the body, ...

Reprogrammable RNA nanoparticles activate only in cancer cells to deliver targeted gene-silencing therapy while avoiding ...

Q2 2025 Earnings Call Transcript August 1, 2025 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.05, ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Starting in the mid-2010s, the University of Oxford pediatrician and immunologist began working with scientists in the South African province of KwaZulu-Natal, with the aim of tracking several hundred ...

These 10 stocks could mint the next wave of millionaires › Ocugen (NASDAQ:OCGN), a biotechnology company developing gene therapies and regenerative medicine solutions for eye diseases, released its ...

Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial ...

Daniel Cressy will be the first patient in Louisiana to complete the gene therapy treatment for sickle cell disease.

The primary safety risks associated with gene therapy include immune reactions and off-target effects in unintended organs, such as the liver, lungs, and spleen. Nevertheless, Ali and Townsend note ...

Gain insights from Ocugen's Q2 2025 earnings call, highlighting clinical advancements, strategic partnerships, BLA milestones for 2026-2027, and ...

Targeted rewriting of the epigenome promises to overcome several challenges in direct gene editing in patient therapies.

Evidence is growing that some HIV-infected infants, if given antiretroviral drugs early in life, are able to suppress their ...